Skip to main content
Top
Published in: Radiation Oncology 1/2011

Open Access 01-12-2011 | Research

Risk factors of distant brain failure for patients with newly diagnosed brain metastases treated with stereotactic radiotherapy alone

Authors: Xiu-jun Chen, Jian-ping Xiao, Xiang-pan Li, Xue-song Jiang, Ye Zhang, Ying-jie Xu, Jian-rong Dai, Ye-xiong Li

Published in: Radiation Oncology | Issue 1/2011

Login to get access

Abstract

Objective

To explore the risk factors of distant brain failure (DBF) for patients with brain metastasis (BM) who were treated with stereotactic radiotherapy alone and to group the patients on the basis of their risk levels.

Methods and Materials

We retrospectively analyzed 132 newly diagnosed BM patients who were treated with stereotactic radiotherapy alone from May 2000 to April 2010. Kaplan-Meier and Cox proportional hazards regression analyses were performed for univariate and multivariate analyses.

Results

The 1-year incidence rate of DBF was 44.7%, and the median DBF time (MDBFT) was 18 months. In multivariate analysis, the risk factors of DBF were the number of BMs greater than 1 (p = 0.041), uncontrolled extracranial disease (p = 0.005), interval time (IT) of less than 60 months between the diagnosis of primary tumor and BM (p = 0.024), and total volume of BM was greater than 6 cc (p = 0.049). Each risk factor was assigned 1 score. The median survival times for the patients with scores of 0-1, 2-3, and 4 were 31, 12, and 10 months, respectively, and the corresponding MDBFTs were not reached, 13, and 3 months, respectively, (p < 0.001). The crude DBF incidence rates in patients with scores of 0-1, 2-3, and 4 were 14.8%, 50.0%, and 76.9%, respectively, (p < 0.001).

Conclusions

The patients with scores of 0-1 had a lower risk of DBF than the patients with higher scores did, and it may be reasonable to treat these patients with SRS alone and resort to whole-brain radiation therapy only for salvage. The patients with a score of 4 had the highest risk of developing DBF after stereotactic radiotherapy alone, these patients may be candidates for initial whole-brain radiation therapy or clinical trials. The patients with a score of 2-3 had a moderate risk of developing DBF, SRT alone combined with close clinical monitoring would be the optimal treatment regimen for such patients, and for those patients with difficulties in receiving close clinical mornitoring, SRT combined with WBRT will be more suitable.
Appendix
Available only for authorised users
Literature
1.
go back to reference Komarnicky LT, Phillips TL, Martz K, et al: A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG 79-16). Int J Radiat Oncol Biol Phys. 1991, 20: 53-58. 10.1016/0360-3016(91)90137-S.CrossRefPubMed Komarnicky LT, Phillips TL, Martz K, et al: A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG 79-16). Int J Radiat Oncol Biol Phys. 1991, 20: 53-58. 10.1016/0360-3016(91)90137-S.CrossRefPubMed
2.
go back to reference Sause WT, Scott C, Kirsch R, et al: Phase I/II trial of accelerated fractionation in brain metastases, RTOG 85-28. Int J Radiat Oncol Biol Phys. 1993, 26: 653-657. 10.1016/0360-3016(93)90284-3.CrossRefPubMed Sause WT, Scott C, Kirsch R, et al: Phase I/II trial of accelerated fractionation in brain metastases, RTOG 85-28. Int J Radiat Oncol Biol Phys. 1993, 26: 653-657. 10.1016/0360-3016(93)90284-3.CrossRefPubMed
3.
go back to reference Phillips TL, Scott CB, Leibel S, et al: Results of a randomized comparison of radiotherapy and bromodeoxyuridine to radiotherapy alone for brain metastases: Report of RTOG trial 89-05. Int J Radiat Oncol Biol Phys. 1995, 33: 339-348. 10.1016/0360-3016(95)00168-X.CrossRefPubMed Phillips TL, Scott CB, Leibel S, et al: Results of a randomized comparison of radiotherapy and bromodeoxyuridine to radiotherapy alone for brain metastases: Report of RTOG trial 89-05. Int J Radiat Oncol Biol Phys. 1995, 33: 339-348. 10.1016/0360-3016(95)00168-X.CrossRefPubMed
4.
go back to reference Murray KJ, Scott C, Greenberg HM, et al: A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastasis: A report of RTOG9104. Int J Radiat Oncol Biol Phys. 1997, 39: 571-574. 10.1016/S0360-3016(97)00341-6.CrossRefPubMed Murray KJ, Scott C, Greenberg HM, et al: A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastasis: A report of RTOG9104. Int J Radiat Oncol Biol Phys. 1997, 39: 571-574. 10.1016/S0360-3016(97)00341-6.CrossRefPubMed
5.
go back to reference Chang EL, Wefel JS, Hess KR, et al: Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009, 10: 1037-44. 10.1016/S1470-2045(09)70263-3.CrossRefPubMed Chang EL, Wefel JS, Hess KR, et al: Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009, 10: 1037-44. 10.1016/S1470-2045(09)70263-3.CrossRefPubMed
6.
go back to reference Aoyama H, Shirato H, Tago M, et al: Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial. JAMA. 2006, 295: 2483-2491. 10.1001/jama.295.21.2483.CrossRefPubMed Aoyama H, Shirato H, Tago M, et al: Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial. JAMA. 2006, 295: 2483-2491. 10.1001/jama.295.21.2483.CrossRefPubMed
7.
go back to reference Kocher M, Soffietti R, Abacioglu U, et al: Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study. J Clin Oncol. 2011, 29 (2): 134-141. 10.1200/JCO.2010.30.1655.PubMedCentralCrossRefPubMed Kocher M, Soffietti R, Abacioglu U, et al: Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study. J Clin Oncol. 2011, 29 (2): 134-141. 10.1200/JCO.2010.30.1655.PubMedCentralCrossRefPubMed
8.
go back to reference Sawrie SM, Guthrie Bl, Spencer SA, et al: Predictors Of Distant Brain Recurrence For Patients With Newly Diagnosed Brain Metastases Treated With Stereotactic Radiosurgery Alone. Int J Radiat Oncol Biol Phys. 2008, 70 (1): 181-186. 10.1016/j.ijrobp.2007.05.084.CrossRefPubMed Sawrie SM, Guthrie Bl, Spencer SA, et al: Predictors Of Distant Brain Recurrence For Patients With Newly Diagnosed Brain Metastases Treated With Stereotactic Radiosurgery Alone. Int J Radiat Oncol Biol Phys. 2008, 70 (1): 181-186. 10.1016/j.ijrobp.2007.05.084.CrossRefPubMed
9.
go back to reference Radbill AE, Fiveash JF, Falkenberg ET, et al: Initial Treatment of Melanoma Brain Metastases Using Gamma Knife Radiosurgery. Cancer. 2004, 101 (4): 825-833. 10.1002/cncr.20447.CrossRefPubMed Radbill AE, Fiveash JF, Falkenberg ET, et al: Initial Treatment of Melanoma Brain Metastases Using Gamma Knife Radiosurgery. Cancer. 2004, 101 (4): 825-833. 10.1002/cncr.20447.CrossRefPubMed
10.
go back to reference Lutterbach J, Cyron D, Henne K, Ostertag CB: Radiosurgery followed by planned observation in patients with one to three brain metastases. Neurosurgery. 2008, 62 (2): 776-84.PubMed Lutterbach J, Cyron D, Henne K, Ostertag CB: Radiosurgery followed by planned observation in patients with one to three brain metastases. Neurosurgery. 2008, 62 (2): 776-84.PubMed
11.
go back to reference Yu CH, Chen JCT, Apuzzo MLJ, et al: Metastatic Melanoma To The Brain: Prognostic Factors After Gamma Knife Radiosurgery. Int J Radiat Oncol Biol Phys. 2002, 52 (5): 1277-1287. 10.1016/S0360-3016(01)02772-9.CrossRefPubMed Yu CH, Chen JCT, Apuzzo MLJ, et al: Metastatic Melanoma To The Brain: Prognostic Factors After Gamma Knife Radiosurgery. Int J Radiat Oncol Biol Phys. 2002, 52 (5): 1277-1287. 10.1016/S0360-3016(01)02772-9.CrossRefPubMed
12.
go back to reference Matsunaga S, Shuto T, Kawahara N, Suenaga J, Inomori S, Fujino HJ: Gamma Knife surgery for metastatic brain tumors from primary breast cancer: treatment indication based on number of tumors and breast cancer phenotype. Neurosurg. 2010, 113 (1): 65-72. Matsunaga S, Shuto T, Kawahara N, Suenaga J, Inomori S, Fujino HJ: Gamma Knife surgery for metastatic brain tumors from primary breast cancer: treatment indication based on number of tumors and breast cancer phenotype. Neurosurg. 2010, 113 (1): 65-72.
13.
go back to reference Knisely JPS, Berkey B, Chakravarti A, et al: A Phase III Study Of Conventional Radiation Therapy Plus Thalidomide Versus Conventional Radiation Therapy For Multiple Brain Metastases (RTOG 0118). Int J Radiat Oncol Biol Phys. 2008, 71 (1): 79-86. 10.1016/j.ijrobp.2007.09.016.CrossRefPubMed Knisely JPS, Berkey B, Chakravarti A, et al: A Phase III Study Of Conventional Radiation Therapy Plus Thalidomide Versus Conventional Radiation Therapy For Multiple Brain Metastases (RTOG 0118). Int J Radiat Oncol Biol Phys. 2008, 71 (1): 79-86. 10.1016/j.ijrobp.2007.09.016.CrossRefPubMed
14.
go back to reference Higuchi Y, Serizawa T, Nagano O, et al: Three-Staged Stereotactic Radiotherapy Without Whole Brain Irradiation For Large Metastatic Brain Tumors. Int J Radiat Oncol Biol Phys. 2009, 74 (5): 1543-1548. 10.1016/j.ijrobp.2008.10.035.CrossRefPubMed Higuchi Y, Serizawa T, Nagano O, et al: Three-Staged Stereotactic Radiotherapy Without Whole Brain Irradiation For Large Metastatic Brain Tumors. Int J Radiat Oncol Biol Phys. 2009, 74 (5): 1543-1548. 10.1016/j.ijrobp.2008.10.035.CrossRefPubMed
15.
go back to reference Aoyama H, Tago M, Kato N, et al: Neurocognitive Function Of Patients With Brain Metastasis Who Received Either Whole Brain Radiotherapy Plus Stereotactic Radiosurgery Or Radiosurgeryalone. Int J Radiat Oncol Biol Phys. 2007, 68 (5): 1388-1395. 10.1016/j.ijrobp.2007.03.048.CrossRefPubMed Aoyama H, Tago M, Kato N, et al: Neurocognitive Function Of Patients With Brain Metastasis Who Received Either Whole Brain Radiotherapy Plus Stereotactic Radiosurgery Or Radiosurgeryalone. Int J Radiat Oncol Biol Phys. 2007, 68 (5): 1388-1395. 10.1016/j.ijrobp.2007.03.048.CrossRefPubMed
16.
go back to reference Meyers CA, Wefel JS: The use of the Mini-Mental State Examination to assess cognitive functioning in cancer trials: No ifs, ands, or buts, or sensitivity. J Clin Oncol. 2003, 21: 3557-3558. 10.1200/JCO.2003.07.080.CrossRefPubMed Meyers CA, Wefel JS: The use of the Mini-Mental State Examination to assess cognitive functioning in cancer trials: No ifs, ands, or buts, or sensitivity. J Clin Oncol. 2003, 21: 3557-3558. 10.1200/JCO.2003.07.080.CrossRefPubMed
Metadata
Title
Risk factors of distant brain failure for patients with newly diagnosed brain metastases treated with stereotactic radiotherapy alone
Authors
Xiu-jun Chen
Jian-ping Xiao
Xiang-pan Li
Xue-song Jiang
Ye Zhang
Ying-jie Xu
Jian-rong Dai
Ye-xiong Li
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2011
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/1748-717X-6-175

Other articles of this Issue 1/2011

Radiation Oncology 1/2011 Go to the issue